BioSante Pharmaceuticals to Present at Two International Health Care Conferences
Lincolnshire, Illinois (May 14, 2008) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO, will present a corporate update and overview at two upcoming international healthcare conferences. Mr. Simes will discuss the LibiGel® (testosterone gel) clinical development plan and new primary research data indicating the potential size of the U.S. market for BioSanteís LibiGel in the treatment of female sexual dysfunction. Both conferences will feature pharmaceutical and biotech companies presenting to institutional investors, portfolio managers and analysts from around the world interested in these sectors.
The first conference is the Rodman & Renshaw Annual Global Healthcare Conference. Mr. Simes will be presenting on Monday, May 19, 2008 at 8:30 am EDT.
The second conference is the BIOMED ISRAEL 2008 Healthcare Conference. Mr. Simes will be presenting on Wednesday, May 28, 2008 at 9:55 am EDT.
A live audio webcast of BioSanteís presentation at the Rodman & Renshaw Conference may be accessed at http://www.biosantepharma.com/Webcasts.php and a replay will be available at the same link for 60 days.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of products to treat both men and women. These products are gel formulations for transdermal administration that deliver estradiol and testosterone. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Nycomed US, BioSante’s licensee. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.